Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
Pharvaris N.V. President Lu Peng reported two direct common-stock withholdings: 117 shares on October 12, 2026, and 109 shares on October 11, 2026. The issuer withheld the shares to satisfy tax withholding obligations upon vesting of restricted stock units. Both transaction rows report $31.10 per share; these were tax-withholding dispositions.
Pharvaris N.V. director Viviane Monges exercised options to acquire 11,969 common shares on September 23, 2026, at an exercise price of $8.05 per share, then sold 11,969 shares in a cashless exercise. The sale price was a weighted average of $33.0457 per share, with individual prices ranging from $33.00 to $33.0801. The reported option balance after the exercise was 9,031, with an expiration date of April 6, 2033.
Pharvaris N.V. President Lu Peng exercised options to acquire 45,308 common shares on September 22, 2026, at an exercise price of $2.5900 per share. After the transaction, he directly held 110,261 common shares. The options vested 25% on February 3, 2021, with the remaining shares vesting in 1/48 monthly installments thereafter.
Pharvaris N.V. director Johannes Gerardus Christiaan Petrus Schikan exercised 800 stock options on September 22, 2026, at a $20 exercise price, acquiring 800 common shares and selling 800 shares in a cashless exercise transaction. The sale price was a weighted average $36.19 per share, with transaction prices from $36.15 to $36.23. The stock-option line reports 34,200 shares following the transaction; no Rule 10b5-1 plan is reported.
Pharvaris N.V. Director Viviane Rosine Francoise Beck Monges reported a proposed sale of 11,969 Common shares, with an aggregate market value of $395,523.98 and an approximate sale date of September 23, 2026. The shares are listed as acquired from the issuer through exercise of options under a registered plan, with cash shown as the payment method. Morgan Stanley Smith Barney LLC Executive Financial Services is listed as broker.
Pharvaris N.V. (PHVS) CFO / CLO David W. Nassif reported selling 6,000 common shares on September 21, 2026, at a weighted average price of $36.4668 per share. The shares were sold in multiple transactions at prices ranging from $36.30 to $36.71 and had been acquired upon vesting of restricted stock units on various dates. Nassif also reported giving 500 common shares to a charitable organization on September 21, 2026. No Rule 10b5-1 plan is reported.
Pharvaris N.V. (PHVS) is named as the issuer in an amended Form 144 notice covering planned sales of 200,000 shares of common stock for the account of Johannes Gerardus Christiaan Petrus Schikan. The shares are to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $7,000,000, and Pharvaris reports 65,210,590 common shares outstanding as of September 17, 2026.
The securities to be sold were acquired on December 23, 2015 as founder stock from the issuer for cash. Over the past three months, Schikan has sold Pharvaris common shares in several transactions, including 30,712 shares for $1,090,048.73 on June 30, 2026. The amendment states it is being filed to update the amount of securities sold and gross proceeds for the June 30, 2026 trade.
Pharvaris N.V. (PHVS) director Johannes Gerardus Christiaan Petrus Schikan filed a notice of proposed sale of Pharvaris common shares under Rule 144. The filing indicates an intent to sell 800 common shares on September 22, 2026, to be acquired through the exercise of options under a registered plan for cash.
The notice also lists prior sales of Pharvaris common stock by the same person during the preceding three months, including transactions on June 29, June 30, and September 17, 2026, each reporting share amounts and aggregate proceeds.
Pharvaris N.V. (PHVS) reported that President Lu Peng exercised stock options and sold shares on September 17, 2026. Options for 100,000 shares of common stock were exercised at an exercise price of $2.59 per share, and the resulting 100,000 shares of common stock were then sold at $35.00 per share. No Rule 10b5-1 trading plan is reported for these transactions.
Pharvaris N.V. (PHVS) director Johannes Gerardus Christiaan Petrus Schikan reported selling 200,000 shares of common stock on September 17, 2026, at $35.00 per share in an open-market or private transaction. After this sale, he holds 115,167 shares directly, and no Rule 10b5-1 trading plan is reported.